FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HILZINGER KURT J					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]					(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
	TLOOK TH	IERAPEUTICS,		10	3. Date of Earliest Transaction (Month/Day/Year) 10/05/2021							Officer below)	(give title	Other below)	specify
(Street)	N.	TH, BUILDING	08830	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	•	(Zip)		- 0-					-f D					
Date (Month/D			Fransaction te onth/Day/Y	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transactic Code (Ins 8) Code V	4. Secur Dispose 5) Amount	urities Acquired (A) or led Of (D) (Instr. 3, 4 and t (A) or Price		5. Amount of Securities For Beneficially (D) Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(e.g 3A. Deemed Execution Date, if any (Month/Day/Yea	4. Transa Code (ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		pate Expiration Date Expiration Date (Month/Day/Year) Expiration Date Expiration Date Expiration		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		8. Price of Derivative Security (Instr. 5) (Instr. 5) Reported Transacti (Instr. 4)		Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
Stock Option (Right to Buy)	\$2.12	10/05/2021		A		34,425		(1)	10/05/2031	Common Stock	34,425	\$0.00	34,425	D	

Explanation of Responses

1. The options were granted under the 2015 Plan in lieu of \$60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Remarks:

/s/ Lawrence A. Kenyon, Attorney-in-Fact

10/07/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.